RxDoctor Payments Data

Juan Crespo, MD

Family Medicine · Ocala, FLNPI 1609824879

Payments from drug & device makers

$2,542in general payments, 2019–2025

Across 125 payments — averaging $20.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$987
  • Novo Nordisk$222
  • Lilly USA, LLC$201
  • Astellas Pharma US Inc$193
  • AstraZeneca$176
  • Boehringer Ingelheim$142
  • plus $620 from 16 others

What the payments were for

  • Food & beverage$2,44896%
  • Education$944%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,542 in reported general payments places this provider in the 75th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$96,849
Medicare patients
288
Services billed
22,859

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide117$117,057
EliquisApixaban95$91,985
JanuviaSitagliptin Phosphate52$75,106
TrulicityDulaglutide43$59,335
MounjaroTirzepatide42$58,410
OdefseyEmtricitab/Rilpiviri/Tenof Ala13$49,493
JardianceEmpagliflozin40$47,518
EntrestoSacubitril/Valsartan15$25,608
BelsomraSuvorexant33$15,754
VascepaIcosapent Ethyl13$14,185
Repatha SureclickEvolocumab12$13,432
MyrbetriqMirabegron21$10,472
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$9,695
FarxigaDapagliflozin Propanediol12$8,223
LantusInsulin Glargine,hum.Rec.Anlog15$7,814

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$201$117,74485 claims
Novo NordiskOzempic$222$117,057117 claims
PfizerEliquis$81$91,98595 claims
MerckJanuvia, Belsomra$85$90,86085 claims
Boehringer IngelheimJardiance$142$47,51840 claims
NovartisEntresto$23$25,60815 claims
Astellas Pharma US IncMyrbetriq$193$10,47221 claims
GSKAnoro Ellipta$15$9,69518 claims
AstraZenecaFarxiga$176$8,22312 claims
Sanofi-aventis U.S. LLCLantus$23$7,81415 claims
AbbVieSynthroid$987$5,98763 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Ocala

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →